In this multicentre , open-label , randomised phase II trial , women with HER2-negative LR/MBC were randomly assigned in a 1:1 ratio to paclitaxel ( 90 mg/m2 intravenously [ IV ] on days 1 , 8 , and 15 ) and bevacizumab ( 10 mg/kg IV on days 1 and 15 ) every 4 weeks for six cycles , followed by bevacizumab ( 15 mg/kg IV on day 1 ) every 3 weeks ( AT ) or to paclitaxel ( 90 mg/m2 IV on days 1 and 8 ) , bevacizumab ( 15 mg/kg IV on day 1 ) and capecitabine ( 825 mg/m2 orally twice daily on days 114 ) every 3 weeks for eight cycles , followed by bevacizumab and capecitabine at the same doses every 3 weeks ( ATX ) .